NLRP3 and COVID-19: Given its effectiveness in CNS‐related pathologies such as neuro‐Behçet's syndrome [100] with its well reported efficacy in the suppression of NLRP3 inflammasome [142, 143], colchicine holds great potential for the management of COVID‐19‐associated neuroinflammation [144].